纳米载体药物用于缓解慢性肾脏病纤维化的研究进展

doi:10.3969/j.issn.1000-8535.2022.05.001

广州医药 ›› 2022, Vol. 53 ›› Issue (5): 1-10.DOI: 10.3969/j.issn.1000-8535.2022.05.001

• 专家综述 • 下一篇

纳米载体药物用于缓解慢性肾脏病纤维化的研究进展

李恒亦, 李冬冬, 梁鸣

华南理工大学附属第二医院,广州市第一人民医院肾内科(广州 510180)

收稿日期:2022-05-15 出版日期:2022-09-20 发布日期:2022-10-11
通讯作者: 梁鸣,E-mail:liangming1972@126.com; 李冬冬, E-mail:mcddli@mail.scut.edu.cn
作者简介:梁鸣,博士,主任医师/教授,华南理工大学硕士和博士研究生导师,博士后合作导师。美国贝勒医学院博士后,广东省杰出青年医学人才(2017年度)、广州市医学重点人才(2018、2020年度); “胡润平安中国好医生”(2017年度)、第四届“羊城好医生”(2018年度);广东省医学会肾脏病分会委员、广东省医师协会肾脏病分会委员、广东省生物医学工程学会常委、广东省药学会肾脏病用药专家委员会常委、广州市医学会肾脏病分会副主任委员,国家自然科学基金函审专家;Kidney International、Therapeutics and Clinical Risk Management等期刊审稿人。
研究方向:主要从事急、慢性肾脏病和动静脉内瘘内膜增生机制及治疗研究。主持或参与国家自然科学基金面上项目4项,广东省自然科学基金、广州市科技计划等省部级项目4项,美国国立卫生研究院(NIH)项目1项;在国内外核心期刊发表论文50余篇,其中第一作者/通讯作者在JASN、KI等肾脏病领域国际权威期刊发表SCI论文4篇。
基金资助:
国家自然科学基金(82170761);中国博士后科学基金(2020M682664);广东省基础与应用基础研究基金青年基金(2021A1515110934)

Recent advances in nanomedicines for alleviating chronic kidney disease fibrosis

LI Hengyi, LI Dongdong, LIANG Ming

Department of Nephrology, Guangzhou First People's Hospital, the Second Affiliated Hospital, South China University of Technology, Guangzhou 510180, China

Received:2022-05-15 Online:2022-09-20 Published:2022-10-11

摘要/Abstract

摘要： 慢性肾脏病是一类具有高发病率、高死亡率的慢性疾病群。临床上一般采用血液透析和肾脏移植治疗终末期的慢性肾脏病。研究表明,小分子药物或核酸类药物在慢性肾脏病治疗中极具潜力,但是缺乏特异性导致肾脏纤维化治疗效果有限,亟需开发新的治疗策略。纳米载体因具有良好的理化性质,被广泛应用于生物医学领域。本文综述了近年来纳米载体递送小分子或核酸类药物在慢性肾脏病中的研究进展。

关键词: 慢性肾脏病, 纳米药物, 肾脏递送, 抗纤维化治疗

Abstract: Chronic kidney disease (CKD) is a series of chronic disease groups associated with high morbidity and mortality. Hemodialysis and kidney transplantation are the only choices for end-stage renal disease. According to the literature report, it is shown that small molecule and nucleic acid drugs have great potential in CKD treatments with an unsatisfied therapeutic efficacy because of the lack of specific targeting. Thus, it is necessary to develop a new strategy. Nanocarriers have been widely used in biomedical fields due to their excellent physical and chemical properties. In this review, we have summarized the recent advances in applying functional nanocarriers to deliver the small molecules and nucleic acid drugs in the treatment of CKD.

Key words: chronic kidney disease, nanomedicines, renal delivery, antifibrotic therapy

李恒亦, 李冬冬, 梁鸣. 纳米载体药物用于缓解慢性肾脏病纤维化的研究进展[J]. 广州医药, 2022, 53(5): 1-10.

LI Hengyi, LI Dongdong, LIANG Ming. Recent advances in nanomedicines for alleviating chronic kidney disease fibrosis[J]. Guangzhou Medical Journal, 2022, 53(5): 1-10.

参考文献

[1] RUIZ-ORTEGA M, RAYEGO-MATEOS S, LAMAS S, et al. Targeting the progression of chronic kidney disease[J]. Nat Rev Nephrol, 2020, 16(5): 269-288.
[2] DENG Y, LI N, WU Y, et al. Global, regional, and national burden of diabetes-related chronic kidney disease from 1990 to 2019[J]. Front endocrinol, 2021(12): 672350.
[3] FOREMAN K J, MARQUEZ N, DOLGERT A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories[J]. Lancet, 2018, 392(10159): 2052-2090.
[4] UMPHREYS B D. Mechanisms of renal fibrosis[J]. Annu Rev Physiol, 2018(80): 309-326.
[5] CHEN T K, KNICELY D H, GRAMS M E. Chronic kidney disease diagnosis and management: a review[J]. J Am Med Assoc, 2019, 322(13): 1294-1304.
[6] ROBERTS T C, LANGER R, WOOD M J A. Advances in oligonucleotide drug delivery[J]. Nat Rev Drug Discov, 2020, 19(10): 673-694.
[7] HUANG L, YANG J, WANG T, GAO J, et al. Engineering of small-molecule lipidic prodrugs as novel nanomedicines for enhanced drug delivery[J]. J Nanobiotechnol, 2022, 20(1): 49.
[8] KAMALY N, HE J C, AUSIELLO D A, et al. Nanomedicines for renal disease: current status and future applications[J]. Nat Rev Nephrol, 2016, 12(12): 738-753.
[9] STATER E P, SONAY A Y, HART C, et al. The ancillary effects of nanoparticles and their implications for nanomedicine[J]. Nat Nanotechnol, 2021, 16(11): 1180-1194.
[10] FALKE L L, GHOLIZADEH S, GOLDSCHMEDING R, et al. Diverse origins of the myofibroblast-implications for kidney fibrosis[J]. Nat Rev Nephrol, 2015, 11(4): 233-244.
[11] WOO K-T, CHOONG H L, WONG K-S, et al. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases[J]. Kidney Int, 2012, 81(10): 1044-1045.
[12] BOOR P, OSTENDORF T, FLOEGE J. Renal fibrosis: novel insights into mechanisms and therapeutic targets[J]. Nat Rev Nephrol, 2010, 6(11): 643-656.
[13] WIGHT T N, POTTER-PERIGO S. The extracellular matrix: an active or passive player in fibrosis?[J] Am J Physiol Gastr L, 2011, 301(6): G950-955.
[14] SATCHELL S C, BRAET F. Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier[J]. Am J Physiol Renal, 2009, 296(5): F947-F956.
[15] CURRY F E, ADAMSON R H. Endothelial glycocalyx: permeability barrier and mechanosensor[J]. Ann Biomed Eng, 2012, 40(4): 828-839.
[16] SUH J H, MINER J H. The glomerular basement membrane as a barrier to albumin[J]. Nat Rev Nephrol, 2013, 9(8): 470-477.
[17] KANWAR Y S, FARQUHAR M G. Presence of heparan sulfate in the glomerular basement membrane[J]. P Natl Acad Sci USA, 1979, 76(3), 1303-1307.
[18] OGAWA S, OTA Z, SHIKATA K, et al. High-resolution ultrastructural comparison of renal glomerular and tubular basement membranes[J]. Am J Nephrol, 1999, 19(6): 686-693.
[19] SANCEY L, KOTB S, TRULLLET C, et al. Long-term in vivo clearance of gadolinium-based aguix nanoparticles and their biocompatibility after systemic injection[J]. ACS Nano, 2015, 9(3): 2477-2488.
[20] WILLIAMS R M, SHAH J, NG B D, et al. Mesoscale nanoparticles selectively target the renal proximal tubule epithelium[J]. Nano Lett, 2015, 15(4): 2358-2364.
[21] LI S, ZHANG H, CHEN K, et al. Application of chitosan/alginate nanoparticle in oral drug delivery systems: prospects and challenges[J]. Drug Deliv, 2022, 29(1): 1142-1149.
[22] LIN L, SUN Y, WANG D, et al. Celastrol ameliorates ulcerative colitis-related colorectal cancer in mice via suppressing inflammatory responses and epithelial-mesenchymal transition[J]. Front Pharmacol, 2016(6): 320.
[23] LI R, LI Y, ZHANG J, et al. Targeted delivery of celastrol to renal interstitial myofibroblasts using fibronectin-binding liposomes attenuates renal fibrosis and reduces systemic toxicity[J]. J Control Release, 2020(320): 32-44.
[24] FAN J M, NG Y Y, HILL P A, et al. Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro[J]. Kidney Int, 1999, 56(4): 1455-1467.
[25] GUO P, WANG J, GAO W, et al. Salvianolic acid B reverses multidrug resistance in nude mice bearing human colon cancer stem cells[J]. Mol Med Rep, 2018, 18(2): 1323-1334.
[26] LI J, ZHANG C, HE W, et al. Coordination-driven assembly of catechol-modified chitosan for the kidney-specific delivery of salvianolic acid B to treat renal fibrosis[J]. Biomater Sci, 2017, 6(1): 179-188.
[27] QIAO H, SUN M, SU Z, et al. Kidney-specific drug delivery system for renal fibrosis based on coordination-driven assembly of catechol-derived chitosan[J]. Biomaterials, 2014, 35(25): 7157-7171.
[28] WANG X, DENG B, YU M, et al. Constructing a passive targeting and long retention therapeutic nanoplatform based on water-soluble, non-toxic and highly-stable core-shell poly(amino acid) nanocomplexes[J]. Biomater Sci, 2021, 9(21): 7065-7075.
[29] VITIELLO P P, CARDONE C, MARTINI G, et al. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines[J]. J Exp Clin Canc Res, 2019, 38(1): 1-12.
[30] LIU B C, LAN H Y, LV L L. Renal Fibrosis: Mechanisms and Therapies[M]. Springer Singapore, 2019.
[31] WANG Z, LIN Q, DAI W, et al. Pioglitazone downregulates Twist-1 expression in the kidney and protects renal function of Zucker diabetic fatty rats[J]. Biomed Pharmacother, 2019(118): 109346.
[32] WEI S, XU C, ZHANG Y, et al. Ultrasound assisted a peroxisome proliferator-activated receptor (PPAR)gamma agonist-loaded nanoparticle-microbubble complex to attenuate renal interstitial fibrosis[J]. Int J Nanomed, 2020(15): 7315-7327.
[33] BRODY H. GENE THERAPY[J]. Nature, 2018, 564(7735): S5-S5.
[34] ZHAO Z, WANG J, MAO H Q,et al. Polyphosphoesters in drug and gene delivery[J]. Adv Drug Delivery Rev, 2003, 55(4): 483-499.
[35] SUBHAN M A, TORCHILIN V P. siRNA based drug design, quality, delivery and clinical translation[J]. Nanomed-Nanotechnol, 2020(29): 102239.
[36] STOKMAN G, QIN Y, RACZ Z, et al. Application of siRNA in targeting protein expression in kidney disease[J]. Adv Drug Delivery Rev, 2010, 62(14): 1378-1389.
[37] YANG C, NILSSON L, CHEEMA M U, et al. Chitosan/siRNA nanoparticles targeting cyclooxygenase type 2 attenuate unilateral ureteral obstruction-induced kidney injury in mice[J]. Theranostics, 2015, 5(2): 110-123.
[38] PENG B, CHEN Y, LEONG K W. MicroRNA delivery for regenerative medicine[J]. Adv Drug Delivery Rev, 2015(88): 108-122.
[39] LI C, WANG N, RAO P, et al. Role of the microRNA-29 family in myocardial fibrosis[J]. J Physiol Biochem, 2021, 77(3): 365-376.
[40] LI Y F, JING Y, HAO J, et al. MicroRNA-21 in the pathogenesis of acute kidney injury[J]. Protein Cell, 2013, 4(11): 813-819.
[41] WANG B, KOMERS R, CAREW R, et al. Suppression of microRNA-29 expression by tgf-beta 1 promotes collagen expression and renal fibrosis[J]. J Am Soc Nephrol, 2012, 23(2): 252-265.
[42] HE Y, HUANG C, LIN X, LI J. MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases[J]. Biochimie, 2013, 95(7): 1355-1359.
[43] XU Y, NIU Y, WU B, et al. Extended-release of therapeutic microRNA via a host-guest supramolecular hydrogel to locally alleviate renal interstitial fibrosis[J]. Biomaterials, 2021(275): 120902.
[44] GENG X, ZHANG M, LAI X, et al. Small-sized cationic miRi-PCNPs selectively target the kidneys for high-efficiency antifibrosis treatment[J]. Adv Healthc Mater, 2018, 7(21): 1800558.
[45] MUMPER R J, CUI Z R. Genetic immunization by jet injection of targeted pDNA-coated nanoparticles[J]. Methods, 2003, 31(3): 255-262.
[46] MIDGLEY A C, WEI Y, ZHU D,et al. Multifunctional natural polymer nanoparticles as antifibrotic gene carriers for CKD therapy[J]. J Am Soc Nephrol, 2020, 31(10): 2292-2311.
[47] WANG P, MIN D, CHEN G, et al. Inorganic nanozymes: prospects for disease treatments and detection applications[J]. Front Chem, 2021(9):773285.
[48] NELSON B C, JOHNSON M E, WALKER M L, et al. Antioxidant cerium oxide nanoparticles in biology and medicine[J]. Antioxid, 2016, 5(2): 15.
[49] WANG M, ZENG F, NING F, et al. Ceria nanoparticles ameliorate renal fibrosis by modulating the balance between oxidative phosphorylation and aerobic glycolysis[J]. J Nanobiotechnol, 2022, 20(1): 1-18.
[50] SAIFI M A, PEDDAKKULAPPAGARI C S, AHMAD A, et al. Leveraging the pathophysiological alterations of obstructive nephropathy to treat renal fibrosis by cerium oxide nanoparticles[J]. ACS Biomater Sci Eng, 2020, 6(6): 3563-3573.
[51] ZHENG Z, DENG G, QI C, et al. Porous Se@SiO₂ nanospheres attenuate ischemia/reperfusion (I/R)-induced acute kidney injury (AKI) and inflammation by antioxidative stress[J]. Int J Nanomed, 2019(14): 215-229.
[52] NORDQUIST L, FRIEDERICH-PERSSON M, FASCHING A, et al. Activation of hypoxia-inducible factors prevents diabetic nephropathy[J]. J Am Soc Nephrol, 2015, 26(2): 328-338.
[53] TANAKA T, KOJIMA I, OHSE T, et al. Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model[J]. Lab Invest, 2005, 85(10): 1292-1307.
[54] TAN L, LAI X, ZHANG M, et al. A stimuli-responsive drug release nanoplatform for kidney-specific anti-fibrosis treatment[J]. Biomater Sci, 2019, 7(4): 1554-1564.
[55] SHARMA S, MASUD M K, KANETI Y V, et al. Extracellular vesicle nanoarchitectonics for novel drug delivery applications[J]. Small, 2021, 17(42): 2102220.
[56] TANG T T, LV L L, WANG B,et al. Employing macrophage-derived microvesicle for kidney-targeted delivery of dexamethasone: an efficient therapeutic strategy against renal inflammation and fibrosis[J]. Theranostics, 2019, 9(16): 4740-4755.
[57] JI C, ZHANG J, ZHU Y, et al. Exosomes derived from hucMSC attenuate renal fibrosis through CK1 delta/beta-TRCP-mediated YAP degradation[J]. Cell Death Dis, 2020, 11(5): 1-10.
[58] HILL B D, ZAK A, KHERA E, et al. Engineering virus-like particles for antigen and drug delivery[J]. Curr Protein Pept Sc, 2018, 19(1): 112-127.
[59] ZHANG X, CHEN Q, ZHANG L,et al. Tubule-specific protein nanocages potentiate targeted renal fibrosis therapy[J]. J Nanobiotechnol, 2021, 19(1): 1-17.
[60] ELZOGHBY A O, SAMY W M, ELGINDY N A. Albumin-based nanoparticles as potential controlled release drug delivery systems[J]. J Control Release, 2012, 157(2): 168-182.
[61] HUANG H, LIU Q, ZHANG T, et al. Farnesylthiosalicylic acid-loaded albumin nanoparticle alleviates renal fibrosis by inhibiting Ras/Raf1/p38 signaling pathway[J]. Int J Nanomed, 2021(16): 6441-6453.

纳米载体药物用于缓解慢性肾脏病纤维化的研究进展

Recent advances in nanomedicines for alleviating chronic kidney disease fibrosis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价